112 related articles for article (PubMed ID: 38508144)
1. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Lochmann TL; Powell KM; Ham J; Floros KV; Heisey DAR; Kurupi RIJ; Calbert ML; Ghotra MS; Greninger P; Dozmorov M; Gowda M; Souers AJ; Reynolds CP; Benes CH; Faber AC
Sci Transl Med; 2018 May; 10(441):. PubMed ID: 29769286
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes.
Sengupta S; Das S; Crespo AC; Cornel AM; Patel AG; Mahadevan NR; Campisi M; Ali AK; Sharma B; Rowe JH; Huang H; Debruyne DN; Cerda ED; Krajewska M; Dries R; Chen M; Zhang S; Soriano L; Cohen MA; Versteeg R; Jaenisch R; Spranger S; Romee R; Miller BC; Barbie DA; Nierkens S; Dyer MA; Lieberman J; George RE
Nat Cancer; 2022 Oct; 3(10):1228-1246. PubMed ID: 36138189
[TBL] [Abstract][Full Text] [Related]
3. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
4. MYCN oncoprotein targets and their therapeutic potential.
Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
[TBL] [Abstract][Full Text] [Related]
5. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.
Abu-Zaid A; Fang J; Jin H; Singh S; Pichavaram P; Wu Q; Tillman H; Janke L; Rosikiewicz W; Xu B; Van De Velde LA; Guo Y; Li Y; Shendy NAM; Delahunty IM; Rankovic Z; Chen T; Chen X; Freeman KW; Hatley ME; Durbin AD; Murray PJ; Murphy AJ; Thomas PG; Davidoff AM; Yang J
Cell Rep Med; 2024 Mar; 5(3):101468. PubMed ID: 38508144
[TBL] [Abstract][Full Text] [Related]
6. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
7. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
[TBL] [Abstract][Full Text] [Related]
8. KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.
D'Oto A; Fang J; Jin H; Xu B; Singh S; Mullasseril A; Jones V; Abu-Zaid A; von Buttlar X; Cooke B; Hu D; Shohet J; Murphy AJ; Davidoff AM; Yang J
Nat Commun; 2021 Dec; 12(1):7204. PubMed ID: 34893606
[TBL] [Abstract][Full Text] [Related]
9. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
10. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
11. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances with KDM4 Inhibitors and Potential Applications.
Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J
J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights.
Shendy NAM; Zimmerman MW; Abraham BJ; Durbin AD
Cell Rep Med; 2022 May; 3(5):100632. PubMed ID: 35584622
[TBL] [Abstract][Full Text] [Related]
14. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
DuBois SG; Macy ME; Henderson TO
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35522915
[TBL] [Abstract][Full Text] [Related]
15. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
